secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0001999371-25-007790
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix presents positive Phase 3 TNX-102 SL data at EULAR; PDUFA Aug 15, 2025
----------------------------------------------------------------------------

- TNX-102 SL (sublingual cyclobenzaprine) showed statistically significant pain reduction in Phase 3 RESILIENT study at 14 weeks.
- FDA PDUFA goal date for TNX-102 SL is August 15, 2025; if approved, would be first new fibromyalgia drug in >15 years.
- Novel mechanism targets non-restorative sleep by acting on four post-synaptic receptors regulating sleep.
- Non-opioid analgesic designed for transmucosal delivery to bypass first-pass metabolism and reduce norcyclobenzaprine accumulation.
- Data presented at Annual European Congress of Rheumatology (EULAR) 2025 in Barcelona, June 11-14.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125007790/0001999371-25-007790-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125007790/tnxp-8k_06162025.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-007790

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer